Dermorphin
Also known as: Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2
A heptapeptide from frog skin that is 30–40 times stronger than morphine at the mu-opioid receptor. Listed for completeness; the abuse risk is real.
Overview
Dermorphin is a μ-opioid receptor agonist originally isolated from the skin of South American Phyllomedusa frogs. It contains a D-alanine residue at position 2 — unusual for a vertebrate peptide — which protects it from peptidase breakdown and contributes to its extreme potency. We include it on this site for educational completeness, not because we think it belongs in a recreational or wellness protocol. It is, functionally, an opioid: tolerance develops fast, dependence is a real risk, respiratory depression at high doses can kill, and there is no clean line between 'using it for pain' and 'using it for the opioid effect'. Legitimate research use exists in mammals at preclinical stages. Recreational and grey-market use is genuinely dangerous.
Evidence quality
Animal pharmacology characterising potency, receptor binding, and analgesic profile dates to the 1980s. There are no completed human RCTs of dermorphin as a therapeutic. The peptide also surfaced as a doping agent in horse racing in the 2010s — that's what most of the modern news mentions of dermorphin actually refer to.
Benefits & timeline
Benefits
- Potent analgesia at very low doses (the only reason it has any research interest at all)
- Limited CNS penetration in some animal studies — research interest in peripheral analgesia without central addiction signal, not yet borne out in humans
- Resistance to enzymatic degradation, giving a longer duration than endogenous opioid peptides
- Of clinical interest as a template for designing safer mu-agonists, not as a drug itself
Timeline
30 min post-dose
Onset of analgesia and the full opioid effect — sedation, euphoria, respiratory slowing.
1–2 hours
Peak.
4–6 hours
Effect tapers.
Within 1–2 weeks of repeated use
Tolerance development. Doses needed for the same effect climb sharply.
Within weeks
Physical dependence. Withdrawal on cessation matches the conventional opioid withdrawal syndrome.
Dosage protocols
Advanced
500 mcg
as needed
Beginner
100 mcg
as needed
Standard
300 mcg
as needed
Caution: potent opioid analogue; dependency risk.
Titration & adjustment
Strictly as-needed — never scheduled, never daily. Start at 100 mcg subcutaneously. Maximum 500 mcg per dose. Because dermorphin is a potent μ-opioid agonist, tolerance and dependence develop with regular use. Limit to no more than 2–3 doses per week.
Injection timing
Strictly as-needed for severe pain. Subcutaneous, onset 30 minutes, duration 4–6 hours. Never schedule daily — tolerance and dependency develop quickly.
Side effects & contraindications
- severeRespiratory depression — the dose-limiting and life-threatening side effect, especially when combined with alcohol, benzodiazepines, or other CNS depressants.
- severeDependence and addiction. The high potency means small differences in dose translate to large differences in effect, which accelerates the spiral.
- severeOverdose risk from underestimating potency — dermorphin is 30–40× morphine, and harm-reduction tables for morphine do not apply directly.
- moderateSedation, constipation, urinary retention — the full opioid side-effect package.
- moderateNo characterised long-term human safety data outside of research settings.
Contraindications
- Any personal or family history of opioid use disorder — the addiction signal is exactly what you don't want to expose to a more potent agonist
- Concurrent benzodiazepines, alcohol, or any other CNS depressant — the respiratory-depression risk is multiplicative
- Respiratory disease — asthma, COPD, sleep apnoea
- Pregnancy — opioid exposure in pregnancy produces neonatal abstinence syndrome
- No medical supervision — this peptide should not be self-administered outside a clinical setting
Reconstitution & injection
A 5 mg vial reconstituted with 2.5 ml bacteriostatic water gives 2 mg/ml. A 100 mcg starting dose is 0.05 ml, which is 5 units on a U-100 insulin syringe. We deliberately do not provide higher-dose conversions; if you're past the test-dose stage, you're past the point this site can responsibly guide you. Naloxone (Narcan) on hand is not optional — it's the only thing that reverses an opioid overdose, and a single intranasal dose can be the difference between a scary night and a fatal one.
Open calculator pre-filledStorage after reconstitution
Refrigerate at 2–8 °C after reconstitution. Do not freeze. Light-protected. 14–21 days of stability at fridge temperature. Because dermorphin is dosed as-needed for severe pain (not on a schedule), keep small reconstituted volumes and mix fresh batches as needed rather than holding a large volume across months.
Common mistakes
Treating it like an exotic recovery peptide.
Better approach: It is not in the same category as BPC-157 or thymosin. The opioid pharmacology is the dominant feature. If you wouldn't inject yourself with a tincture of morphine, don't inject this.
Underdosing the danger because the substance is a peptide.
Better approach: 'Peptide' is a chemical description, not a safety category. The endorphins are also peptides; so is heroin's molecular cousin in this case. Potency × poor characterisation × grey-market purity is a bad combination.
Mixing with anything sedating.
Better approach: Most opioid overdose deaths involve a second depressant. Alcohol, benzodiazepines, sleep medications, gabapentin — any of them with dermorphin is the configuration that puts people in the ER.
Using it for chronic pain self-management.
Better approach: Chronic pain protocols belong in a pain clinic where the prescriber can adjust, taper, and monitor. The grey-market route gives you no second pair of eyes when things go sideways.
Real-world tips
- Have naloxone in the room before any dose. Intranasal 4 mg is the standard form; one or two doses reverse an overdose long enough for emergency services to arrive.
- Don't be alone. Opioid respiratory depression doesn't wake you up — someone else has to.
- Don't escalate dose to chase the effect. That's the path to dependence and the path to overdose, and they're the same path.
- If you have used it more than a few times and feel the pull to use it again, treat that signal seriously — it's the early phase of dependence and it's the right time to stop.
- Tell your doctor. Real medical guidance beats internet protocols here by a wide margin.
When something else is the better tool
Medically prescribed opioids for legitimate pain
Use instead when: Always — if your pain warrants opioid therapy, the answer is a prescriber, a monitoring plan, and a drug with a known purity and dose. Not a grey-market peptide.
Non-opioid analgesics (NSAIDs, gabapentinoids, duloxetine, topical lidocaine)
Use instead when: For most chronic pain syndromes outside cancer and post-surgical contexts. The risk-benefit math beats opioids of any kind, dermorphin included.
PEA, palmitoylethanolamide
Use instead when: Mild-to-moderate neuropathic pain where the goal is endocannabinoid-style analgesia without the abuse profile. Modest evidence, vastly better safety.
- Why is this on the site at all?
- Because the site is a dictionary, and an honest dictionary doesn't omit difficult entries. We'd rather you read about dermorphin here, in context, with the risks laid out, than encounter it on a forum that promises it's a 'safe natural alternative'. It isn't.
- Is there a safe protocol for recreational use?
- No. Recreational use of a μ-agonist 30× morphine's potency is what addiction medicine calls 'high-risk by definition'. There isn't a dose schedule that makes that math safe.
- Could it ever be useful?
- In a hospital setting with proper monitoring, for severe acute pain in opioid-naive patients, the pharmacology could in principle be useful. That isn't the use case anyone is buying it for in 2026.
- What about peripheral analgesia claims?
- Some animal work suggests dermorphin analogues can produce peripheral analgesia at low doses. The parent compound at recreational doses is centrally active and causes the full opioid syndrome. Don't confuse the two.